RXO, Inc. (RXO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RXO SEC filings page.
RXO, Inc. (RXO) reported $6.1B in revenue over the twelve months to Jun 30, 2026, up 9.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovered sharply in FY2025, but thinner gross margins and heavier overhead kept the operating model below profitability.
The FY2025 recovery did not improve unit economics: revenue rose26.2% from FY2024 while gross margin fell from21.7% to19.7% . That combination indicates added volume was accompanied by weaker economics per revenue dollar, not simply a temporary earnings gap.
Overhead absorbed the recovery. Gross profit reached
Cash generation is near breakeven after reinvestment. FY2025 operating cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of RXO, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
RXO, Inc. has an operating margin of -1.4%, meaning the company loses $1 on every $100 of revenue. This results in a profitability score of 28/100. This is down from -1.2% the prior year.
RXO, Inc.'s revenue surged 26.2% year-over-year to $5.7B, reflecting rapid business expansion. This strong growth earns a score of 83/100.
RXO, Inc. has elevated debt relative to equity (D/E of 0.25), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 5/100, reflecting increased financial risk.
RXO, Inc.'s current ratio of 1.27 indicates adequate short-term liquidity, earning a score of 32/100. The company can meet its near-term obligations, though with limited headroom.
While RXO, Inc. generated $51.0M in operating cash flow, capex of $59.0M consumed most of it, leaving -$8.0M in free cash flow. This results in a low score of 25/100, reflecting heavy capital investment rather than weak cash generation.
RXO, Inc. posts a -6.5% return on equity (ROE), meaning it loses $6 for every $100 of shareholders' equity. This results in a returns score of 27/100. This is up from -18.0% the prior year.
RXO, Inc. scores 3.23, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.7B) relative to total liabilities ($1.7B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
RXO, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
RXO, Inc. reported a net loss of $100.0M while generating $51.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
RXO, Inc. reported an operating loss of $79.0M against $35.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
RXO, Inc. generated $1.8B in revenue in Q2 2026. This represents an increase of 25.0% from the same quarter a year earlier. Against the prior quarter it is up 24.5%.
RXO, Inc.'s EBITDA was $27.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.0% from the same quarter a year earlier. Against the prior quarter it is up 1450.0%.
RXO, Inc. reported -$9.0M in net income in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 75.0%.
RXO, Inc. earned -$0.05 per diluted share (EPS) in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 76.2%.
Cash & Balance Sheet
RXO, Inc. recorded an outflow of $52.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 677.8% from the same quarter a year earlier. Against the prior quarter it is down 116.7%.
RXO, Inc. held $15.0M in cash against $459.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
RXO, Inc.'s gross margin was 17.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.
RXO, Inc.'s operating margin was 0.1% in Q2 2026, reflecting core business profitability. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.
RXO, Inc.'s net profit margin was -0.5% in Q2 2026, showing the share of revenue converted to profit. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.
RXO, Inc.'s ROE was -0.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.
Capital Allocation
RXO, Inc. invested $12.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 29.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
RXO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B+25.0% | $1.4B-0.6% | $1.5B-11.9% | $1.4B+36.6% | $1.4B+52.6% | $1.4B+57.0% | $1.7B+70.4% | $1.0B+6.6% |
| Cost of Revenue | $1.5B+31.7% | $1.2B+1.6% | $1.2B-11.3% | $1.1B+40.5% | $1.1B+59.7% | $1.2B+64.9% | $1.4B+82.6% | $809.0M+9.0% |
| Gross Profit | $302.0M+0.3% | $254.0M-9.3% | $266.0M-14.2% | $284.0M+22.9% | $301.0M+30.9% | $280.0M+30.8% | $310.0M+31.9% | $231.0M-1.3% |
| SG&A Expenses | $211.0M-1.4% | $197.0M-6.2% | $200.0M-8.3% | $208.0M+39.6% | $214.0M+39.0% | $210.0M+44.8% | $218.0M+49.3% | $149.0M+0.7% |
| Operating Income | $1.0M | -$28.0M+6.7% | -$42.0M-75.0% | -$7.0M+65.0% | $0 | -$30.0M-150.0% | -$24.0M-271.4% | -$20.0M-433.3% |
| EBITDA | $27.0M-10.0% | -$2.0M-200.0% | -$14.0M-255.6% | $19.0M+1800.0% | $30.0M+76.5% | $2.0M-50.0% | $9.0M-69.0% | $1.0M-95.5% |
| Interest Expense | $9.0M+12.5% | $9.0M0.0% | $9.0M+12.5% | $9.0M+50.0% | $8.0M0.0% | $9.0M+12.5% | $8.0M0.0% | $6.0M-25.0% |
| Income Tax | $1.0M+200.0% | -$13.0M-62.5% | -$5.0M+37.5% | -$1.0M-200.0% | -$1.0M0.0% | -$8.0M-33.3% | -$8.0M-500.0% | $1.0M+150.0% |
| Net Income | -$9.0M0.0% | -$36.0M-16.1% | -$46.0M-84.0% | -$14.0M+94.2% | -$9.0M-28.6% | -$31.0M-106.7% | -$25.0M-1350.0% | -$243.0M-24200.0% |
| EPS (Basic) | -$0.050.0% | -$0.21-16.7% | -$0.27-1250.0% | -$0.08+95.6% | -$0.05+16.7% | -$0.18-38.5% | -$0.02-300.0% | -$1.81-18000.0% |
| EPS (Diluted) | -$0.050.0% | -$0.21-16.7% | -$0.27 | -$0.08+95.6% | -$0.05 | -$0.18-38.5% | -$0.02 | -$1.81-18000.0% |
| Diluted Shares (Avg) | 170M+0.7% | 169M+0.6% | N/A | 169M+25.7% | 169M | 168M+43.3% | N/A | 134M+14.6% |
Not reported in any period shown, so not listed: R&D Expenses.
RXO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.5B+8.1% | $3.3B-1.1% | $3.3B-4.0% | $3.2B-5.6% | $3.2B+76.6% | $3.3B+83.7% | $3.4B+87.1% | $3.4B+74.3% |
| Current Assets | $1.6B+31.4% | $1.3B+6.4% | $1.3B-1.6% | $1.2B-4.3% | $1.2B+52.6% | $1.3B+63.0% | $1.3B+68.2% | $1.3B+34.1% |
| Cash & Equivalents | $15.0M-16.7% | $21.0M+31.3% | $17.0M-51.4% | $25.0M-54.5% | $18.0M+157.1% | $16.0M+128.6% | $35.0M+600.0% | $55.0M-47.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $1.4B+35.6% | $1.2B+5.7% | $1.2B-0.1% | $1.1B-3.0% | $1.1B+46.9% | $1.1B+60.6% | $1.2B+65.1% | $1.1B+44.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.1B-1.2% | $1.1B-1.2% | $1.1B-1.1% | $1.1B+9.3% | $1.1B+78.6% | $1.1B+78.4% | $1.1B+78.3% | $1.0B+63.0% |
| Total Liabilities | $2.0B+21.1% | $1.8B+2.4% | $1.7B-3.7% | $1.6B-6.8% | $1.6B+30.7% | $1.7B+41.1% | $1.8B+46.4% | $1.7B+28.3% |
| Current Liabilities | $1.2B+39.4% | $1.0B+8.7% | $1.0B-2.5% | $907.0M-4.2% | $880.0M+32.9% | $964.0M+43.0% | $1.1B+56.2% | $947.0M+30.1% |
| Non-Current Liabilities | $726.0M-1.0% | $711.0M-5.6% | $698.0M-5.3% | $714.0M-10.0% | $733.0M+28.1% | $753.0M+38.7% | $737.0M+34.2% | $793.0M+26.3% |
| Long-Term Debt | $459.0M+18.6% | $430.0M+11.1% | $387.0M+10.3% | $387.0M+9.9% | $387.0M+4.6% | $387.0M+10.3% | $351.0M-1.4% | $352.0M-22.0% |
| Total Equity | $1.5B-5.2% | $1.5B-4.9% | $1.5B-4.4% | $1.6B-4.4% | $1.6B+174.3% | $1.6B+172.7% | $1.6B+171.4% | $1.7B+180.0% |
| Retained Earnings | -$429.0M-32.4% | -$420.0M-33.3% | -$384.0M-35.2% | -$338.0M-30.5% | -$324.0M-1925.0% | -$315.0M-3400.0% | -$284.0M-4833.3% | -$259.0M-6575.0% |
Not reported in any period shown, so not listed: Inventory.
RXO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.0M-273.9% | -$7.0M-250.0% | $7.0M+200.0% | $23.0M+428.6% | $23.0M+560.0% | -$2.0M-128.6% | -$7.0M-136.8% | -$7.0M-275.0% |
| Depreciation & Amortization | $26.0M-13.3% | $26.0M-18.8% | $28.0M-15.2% | $26.0M+23.8% | $30.0M+76.5% | $32.0M+100.0% | $33.0M+120.0% | $21.0M+31.3% |
| Stock-Based Compensation | N/A | $7.0M0.0% | N/A | N/A | N/A | $7.0M+40.0% | N/A | N/A |
| Capital Expenditures | $12.0M-14.3% | $17.0M+13.3% | $16.0M+33.3% | $14.0M+27.3% | $14.0M+27.3% | $15.0M+36.4% | $12.0M-33.3% | $11.0M-38.9% |
| Free Cash Flow | -$52.0M-677.8% | -$24.0M-41.2% | -$9.0M+52.6% | $9.0M+150.0% | $9.0M+156.3% | -$17.0M-325.0% | -$19.0M-2000.0% | -$18.0M-28.6% |
| Investing Cash Flow | -$12.0M+33.3% | -$17.0M+32.0% | -$15.0M-25.0% | -$13.0M+98.7% | -$18.0M-63.6% | -$25.0M-127.3% | -$12.0M+36.8% | -$1.0B-5321.1% |
| Financing Cash Flow | $46.0M+1633.3% | $28.0M+300.0% | $0-100.0% | -$3.0M-100.3% | -$3.0M-118.8% | $7.0M+16.7% | $1.0M+101.0% | $1.1B+27225.0% |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
RXO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.0%-4.2pp | 17.8%-1.7pp | 18.1%-0.5pp | 20.0%-2.2pp | 21.2%-3.5pp | 19.5%-3.9pp | 18.6%-5.4pp | 22.2%-1.8pp |
| Operating Margin | 0.1%+0.1pp | -2.0%+0.1pp | -2.9%-1.4pp | -0.5%+1.4pp | 0.0%0.0pp | -2.1%-0.8pp | -1.4%-2.9pp | -1.9%-2.5pp |
| Net Margin | -0.5%+0.1pp | -2.5%-0.4pp | -3.1%-1.6pp | -1.0%+22.4pp | -0.6%+0.1pp | -2.2%-0.5pp | -1.5%-1.7pp | -23.4%-23.3pp |
| Return on Equity | -0.6%0.0pp | -2.4%-0.4pp | -3.0%-1.4pp | -0.9%+13.8pp | -0.6%+0.6pp | -1.9%+0.6pp | -1.6%-1.9pp | -14.7%-14.5pp |
| Return on Assets | -0.3%0.0pp | -1.1%-0.2pp | -1.4%-0.7pp | -0.4%+6.7pp | -0.3%+0.1pp | -0.9%-0.1pp | -0.7%-0.8pp | -7.2%-7.1pp |
| Current Ratio | 1.27-0.1x | 1.270.0x | 1.270.0x | 1.320.0x | 1.35+0.2x | 1.30+0.2x | 1.26+0.1x | 1.330.0x |
| Debt-to-Equity | 0.30+0.1x | 0.280.0x | 0.250.0x | 0.240.0x | 0.24-0.4x | 0.24-0.4x | 0.22-0.4x | 0.21-0.6x |
| Asset Turnover | 0.51+0.1x | 0.440.0x | 0.450.0x | 0.44+0.1x | 0.44-0.1x | 0.43-0.1x | 0.490.0x | 0.31-0.2x |
| FCF Margin | -2.9%-3.6pp | -1.7%-0.5pp | -0.6%+0.5pp | 0.6%+2.4pp | 0.6%+2.4pp | -1.2%-0.8pp | -1.1%-1.2pp | -1.7%-0.3pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| RXO, Inc. RXO | FY2025 | $5.7B | -$100.0M | -1.7% | $4.7B | 33/100 |
| Schneider National, Inc. SNDR | FY2025 | $5.7B | $103.6M | 1.8% | $5.7B | 51/100 |
| Knight-Swift Transportation Holdings Inc. KNX | FY2025 | $7.5B | $65.9M | 0.9% | $10.6B | 29/100 |
| Saia, Inc. SAIA | FY2025 | $3.2B | $255.0M | 7.9% | $9.2B | 58/100 |
| ArcBest Corporation ARCB | FY2025 | $4.0B | $60.1M | 1.5% | $2.9B | 43/100 |
| Werner Enterprises Inc WERN | FY2025 | $3.0B | -$14.4M | -0.5% | $2.0B | 34/100 |
Where RXO, Inc. Ranks
Frequently Asked Questions
What is RXO, Inc.'s annual revenue?
RXO, Inc. (RXO) reported $5.7B in total revenue for fiscal year 2025. This represents a 26.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is RXO, Inc.'s revenue growing?
RXO, Inc. (RXO) revenue grew by 26.2% year-over-year, from $4.5B to $5.7B in fiscal year 2025.
Is RXO, Inc. profitable?
No, RXO, Inc. (RXO) reported a net income of -$100.0M in fiscal year 2025, with a net profit margin of -1.7%.
What is RXO, Inc.'s EBITDA?
RXO, Inc. (RXO) had EBITDA of $37.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does RXO, Inc. have?
As of fiscal year 2025, RXO, Inc. (RXO) had $17.0M in cash and equivalents against $387.0M in long-term debt.
What is RXO, Inc.'s gross margin?
RXO, Inc. (RXO) had a gross margin of 19.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is RXO, Inc.'s operating margin?
RXO, Inc. (RXO) had an operating margin of -1.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is RXO, Inc.'s net profit margin?
RXO, Inc. (RXO) had a net profit margin of -1.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is RXO, Inc.'s return on equity (ROE)?
RXO, Inc. (RXO) has a return on equity of -6.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is RXO, Inc.'s free cash flow?
RXO, Inc. (RXO) recorded an outflow of $8.0M in free cash flow during fiscal year 2025. This represents a 86.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is RXO, Inc.'s operating cash flow?
RXO, Inc. (RXO) generated $51.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are RXO, Inc.'s total assets?
RXO, Inc. (RXO) had $3.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are RXO, Inc.'s capital expenditures?
RXO, Inc. (RXO) invested $59.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is RXO, Inc.'s current ratio?
RXO, Inc. (RXO) had a current ratio of 1.27 as of fiscal year 2025, which is considered adequate.
What is RXO, Inc.'s debt-to-equity ratio?
RXO, Inc. (RXO) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is RXO, Inc.'s return on assets (ROA)?
RXO, Inc. (RXO) had a return on assets of -3.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is RXO, Inc.'s P/E ratio?
RXO, Inc. (RXO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $4.7B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is RXO, Inc.'s price-to-sales ratio?
RXO, Inc. (RXO) trades at 0.8x sales, its market capitalization divided by revenue of $6.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $4.7B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is RXO, Inc.'s Altman Z-Score?
RXO, Inc. (RXO) has an Altman Z-Score of 3.23, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is RXO, Inc.'s Piotroski F-Score?
RXO, Inc. (RXO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are RXO, Inc.'s earnings high quality?
RXO, Inc. (RXO) reported a net loss of $100.0M while generating $51.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can RXO, Inc. cover its interest payments?
RXO, Inc. (RXO) reported an operating loss of $79.0M against $35.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is RXO, Inc.?
RXO, Inc. (RXO) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.